Physical compatibility of magnesium sulfate and sodium bicarbonate in a pharmacy-compounded hemofiltration solution

被引:1
作者
Moriyama, Brad
Henning, Stacey A.
Jin, Haksong [5 ]
Kolf, Michael [5 ]
Rehak, Nadja N. [4 ]
Danner, Robert L. [3 ]
Walsh, Thomas J. [2 ]
Grimes, George J. [1 ]
机构
[1] NIH, Dept Pharm, Ctr Clin, Pharmaceut Dev Sect, Bethesda, MD 20892 USA
[2] NCI, Immunocompromised Host Sect, Pediat Oncol Branch, Bethesda, MD 20892 USA
[3] NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA
[4] NIH, Dept Lab Med, Ctr Clin, Bethesda, MD 20892 USA
[5] NIH, Pharmaceut Dev Sect, Dept Pharm, Ctr Clin, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
Compounding; Concentration; Dextrose; Diluents; Electrolytes; Filtration; Hydrogen ion concentration; Incompatibilities; Magnesium sulfate; Sodium bicarbonate; Solutions; Stability; Storage; PARENTERAL-NUTRITION ADMIXTURES; RENAL REPLACEMENT THERAPY; INORGANIC-PHOSPHATE SALTS; ORGANIC CALCIUM;
D O I
10.2146/ajhp090342
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose. The physical compatibility of magnesium sulfate and sodium bicarbonate in a pharmacy-compounded hemofiltration solution was assessed. Methods. Two bicarbonate-buffered hemofiltration solutions (low- and high-magnesium formulations) were compounded in triplicate. The concentrations of magnesium (15 meq/L) and sodium bicarbonate (50 meq/L) in the high-magnesium formulation were chosen to be somewhat below the concentrations reported as being incompatible in a popular reference. The six hemofiltration bags were stored at 22-25 degrees C without protection from light for 48 hours. Physical compatibility was assessed by visual inspection and microscopy. The pH of the solutions was assayed 3-4 and 52-53 hours after compounding. Electrolyte and glucose concentrations of the solutions were assayed at 3-4 and 50-51 hours after preparation. Results. No particulate matter was observed by visual or microscopic inspection in the compounded hemofiltration solutions at 48 hours. The mean +/- S.D. pH values of the low-magnesium solutions were 8.01 +/- 0.02 and 8.04 +/- 0.02 at 3-4 and 52-53 hours after compounding, respectively. The mean S.D. pH values of the high-magnesium solutions were 7.96 +/- 0.02 and 7.98 +/- 0.01 at 3-4 and 52-53 hours after compounding, respectively. The electrolyte and glucose concentrations in the low- and high-magnesium solutions were similar 3-4 and 50-51 hours after preparation. Conclusion. Magnesium sulfate 1.5 meq/L and sodium bicarbonate 50 meq/L were physically compatible in a pharmacy-compounded hemofiltration solution for 48 hours when stored at 22-25 degrees C without protection from light.
引用
收藏
页码:562 / 565
页数:4
相关论文
共 15 条
[1]   Effects of bicarbonate- and lactate-buffered replacement fluids on cardiovascular outcome in CVVH patients [J].
Barenbrock, M ;
Hausberg, M ;
Matzkies, F ;
de la Motte, S ;
Schaefer, RM .
KIDNEY INTERNATIONAL, 2000, 58 (04) :1751-1757
[2]   Medication errors and patient complications with continuous renal replacement therapy [J].
Barletta, Jeffrey F. ;
Barletta, Gina-Marie ;
Brophy, Patrick D. ;
Maxvold, Norma J. ;
Hackbarth, Richard M. ;
Bunchman, Timothy E. .
PEDIATRIC NEPHROLOGY, 2006, 21 (06) :842-845
[3]   Pediatric convective hemofiltration: Normocarb replacement fluid and citrate anticoagulation [J].
Bunchman, TE ;
Maxvold, NJ ;
Brophy, PD .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 42 (06) :1248-1252
[4]   Stability and compatibility assessment techniques for total parenteral nutrition admixtures: setting the bar according to pharmacopeial standards [J].
Driscoll, DF .
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2005, 8 (03) :297-303
[5]  
Feriani M, 1985, Trans Am Soc Artif Intern Organs, V31, P668
[6]  
*GAMBR REN PROD, 2006, PRISMASOL CALC CHLOR
[7]   The first international consensus conference on continuous renal replacement therapy [J].
Kellum, JA ;
Mehta, RL ;
Angus, DC ;
Palevsky, P ;
Ronco, C .
KIDNEY INTERNATIONAL, 2002, 62 (05) :1855-1863
[8]  
KIERDORF H, 1995, CONTRIB NEPHROL, V116, P38
[9]  
LIDE DR, 2006, CRC HDB CHEM PHYS, V4, P73
[10]   Continuous renal replacement therapies: An update [J].
Manns, M ;
Sigler, MH ;
Teehan, BP .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (02) :185-207